Respiratory - Page 1

Sanofi and Regeneron announce positive Phase 2a Results of Dupilumab in Asthma patients
Wednesday, May 22, 2013 Dupilumab targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha), which modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune...

Ablynx commences pre-clinical development of allergic asthma anti-IgE nanobody
Wednesday, May 08, 2013 Ablynx has commenced pre-clinical development of ALX-0962, an anti-immunoglobulin E (IgE) nanobody, to treat severe allergic...

Asmacure doses first subjects in phase 1/2 trial of ASM-024
Thursday, April 18, 2013 Clinical-stage biopharmaceutical company Asmacure has dosed its first subjects with ASM-024 dry powder for inhalation (DPI) formulation in a phase 1/2...

CytRx completes patient enrolment in NSCLC drug study
Friday, March 01, 2013 Biopharmaceutical research and development company CytRx has completed patient enrolment in a Phase IIb clinical study of its oral retinoid compound, tamibarotene in combination...

GSK obtains FDA approval for inhalational anthrax therapy
Monday, December 17, 2012 GlaxoSmithKline (GSK) has obtained FDA approval for raxibacumab monoclonal anti-toxin to treat inhalational anthrax, caused by Bacillus anthracis, in both adults and...

Theravance begins Phase IIb study of TD-4208
Thursday, December 13, 2012 Theravance has begun a TD-4208 dose ranging Phase IIb study in patients with moderate-to-severe chronic obstructive pulmonary disease...

Immunomic commences patient dosing in Phase I JRC-LAMP-vax vaccine trial
Monday, November 12, 2012 Immunomic Therapeutics (ITI) has dosed the first patient in its Phase I trial of JRC-LAMP-vax vaccine for the treatment of symptoms caused by exposure to Japanese red cedar...

Daiichi Sankyo completes patient enrolment in Hokusai-VTE Phase III study
Friday, October 26, 2012 Daiichi Sankyo has completed enrolment in its Hokusai-VTE Phase III study evaluating edoxaban to treat and prevent reoccurrence of venous thromboembolism (VTE) in patients who have had an...

Arena begins Phase I trial of APD811 for PAH
Tuesday, October 16, 2012 Biopharmaceutical company Arena Pharmaceuticals has begun dosing in its placebo-controlled Phase I multiple-dose clinical trial of APD811 for pulmonary arterial hypertension...

Boehringer completes enrolment of two Phase III studies of nintedanib
Friday, September 28, 2012 Boehringer Ingelheim Pharmaceuticals has announced the completion of clinical trial enrolment in two Phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120) for the...

UTHR, Ascendis partner to develop pulmonary arterial hypertension medication
Friday, September 21, 2012 United Therapeutics (UTHR) has collaborated with Ascendis Pharma to develop a self-injectable treprostinil molecule, the active ingredient in Remodulin (treprostinil) injection, for...

Pulmatrix, CFFT to advance PUR118 as cystic fibrosis therapy
Monday, September 17, 2012 Pulmatrix, a clinical stage biotechnology company, has partnered with Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit drug discovery and development affiliate of the Cystic...

Alnylam ALN-RSV01 reports positive data in Phase 2b study
Thursday, May 31, 2012 Alnylam Pharmaceuticals has announced the top-line results from a Phase 2b trial with ALN-RSV01, an inhaled RNAi therapeutic designed for the treatment of respiratory syncytial virus...

EMA recommends Kalydeco for cystic fibrosis treatment
Tuesday, May 29, 2012 The European Medicines Agency (EMA) has recommended Vertex Pharmaceuticals' Kalydeco (ivacaftor), an orphan-designated medicine, for the treatment of cystic fibrosis in patients aged six years...

Boehringer tiotropium drug found effective against asthma
Thursday, May 24, 2012 A Phase II study conducted by Boehringer Ingelheim has reported positive results for its once-daily tiotropium (spiriva) delivered via the Respimat Soft Mist Inhaler (SMI) in adolescents...

Elevation reveals positive results from EP-101 study
Friday, May 18, 2012 Elevation Pharmaceuticals has announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising...

IDRI joins Aeras to develop vaccine against tuberculosis
Thursday, May 10, 2012 Aeras and the Infectious Disease Research Institute (IDRI) have signed a joint development agreement regarding IDRI's tuberculosis (TB) vaccine candidate,...

Novartis says QVA149 Phase III studies meet primary endpoints
Wednesday, April 04, 2012 The first three Phase III studies of Novartis' QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) have met all the primary endpoints in patients with chronic obstructive pulmonary...

MediciNova concludes patient enrolment in Phase 2 MN-221 study
Thursday, March 22, 2012 MediciNova has concluded patient enrolment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221, used for the treatment of acute exacerbations of asthma...

Merck's AIT shows efficacy against ragweed allergy
Wednesday, March 07, 2012 The Phase III study conducted by Merck has revealed that its investigational allergy immunotherapy tablet (AIT) reduced the total combined score that measured nasal and eye symptoms and use...